Review Article
Sinonasal Malignancies and Charged Particle Radiation Treatment: A Systematic Literature Review
Table 5
Results of studies focusing on toxicity.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1CTCAE versus 4.0, 2One patient experienced bilateral vision loss, 3Doses are expressed in biologically equivalent dose (BED) at α/β = 3, 4Data refer to a wider group of patients with head and neck malignancies, 5Two patients had bilateral visual loss, 6Dry-eye syndrome and epiphora were evaluated with CTCAE v.2.0, all the others with LENT/SOMA, 7CTCAE v. 3.0, OARs: organs at risk, C: carbon ions, P: protons, na: not applicable, ON: optic nerve, OC: optic chiasm, DM: diabetes mellitus, MG: male gender, TD: tumor dose, CMT: chemotherapy, UA: univariate analysis, MA: multivariate analysis, CA: cataract, NLB: nasolacrimal duct blockage, D10, 20, 50, 90: dose to the 10%–20%–50%–90% of the organ considered. |